CSL

CSL Cash Conversion

The Cash Conversion Rate (OCF/Net Income) of CSL (CSL.AX) as of Sep 17, 2026 is -136.18 %. In the previous year, Cash Conversion Rate (OCF/Net Income) was 118.62 % — a change of -214.80% (lower).

Cash Conversion

-136.18 %

YoY

-214.80%

Last updated:

Cash Conversion Rate (OCF/Net Income) of CSL is 2026 -136.18 % . Cash Conversion Rate (OCF/Net Income) of CSL was 2025 118.62 % . It decreases by -214.80% lower compared to the previous year.

The CSL Cash Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion
Date
Cash Conversion
Jan 1, 2019
85.70 USD
Jan 1, 2020
171.49 USD
Jan 1, 2021
203.38 USD
Jan 1, 2022
168.88 USD
Jan 1, 2023
177.99 USD
Jan 1, 2024
104.62 USD
Jan 1, 2025
118.62 USD
Jan 1, 2026
-136.18 USD
The CSL Cash Conversion history
YEARCash ConversionYoY
-136.18 %-214.80%
118.62 %+13.39%
104.62 %-41.22%
177.99 %+5.39%
168.88 %-16.96%
203.38 %+18.59%
171.49 %+100.09%
85.70 %-25.99%
115.80 %+24.24%
93.21 %-4.16%
97.26 %-1.64%
98.88 %-7.32%
106.69 %
Access this data via the Eulerpool API

CSL Stock analysis

What does CSL do? CSL Ltd is a global leading company in the field of biological medicine, manufacturing a wide range of products used in the therapy of diseases. The company is based in Melbourne, Australia, and is one of the largest biotech companies in the country. CSL was founded in 1916 by Australian researcher Frank Macfarlane Burnet. Originally named Commonwealth Serum Laboratories, the company focused on the research and production of vaccines. CSL was then privatized in 1994 and changed its name to CSL Ltd. CSL's business model is based on the production of protein products and plasma derivatives used in immunotherapy, hematology, and transplantation medicine. The company specializes in the production and marketing of products in three main areas: plasma products, vaccines, and animal health. CSL's plasma division includes a variety of products, including intravenous immunoglobulins (IVIG), platelets, and alpha-1 antitrypsin. The company operates a number of plasma centers in the US and Europe to collect raw materials for these products. In the vaccine sector, CSL is primarily involved in the manufacture of influenza vaccines and also offers a range of other vaccines, including vaccines against snake bites and encephalitis. In the field of animal health, CSL produces animal vaccines to prevent viral infections in livestock such as pigs, poultry, and cattle. CSL is committed to research and development to develop new products and improve existing ones. The company has a long history in the research and development of vaccines and immunotherapies and has established a strong presence in this field. The company employs over 27,000 people in 35 countries worldwide and operates production facilities in Australia, the US, Europe, and Asia. CSL's headquarters are located in Parkville, a suburb of Melbourne, Australia. CSL has an impressive track record in terms of growth and profitability and is a stable market leader in its field. The company has achieved solid growth rates in recent years and generated a revenue of $8.5 billion in 2019. CSL is a key player in the global healthcare industry and has established a reputation as a reliable supplier of medical products and services. The company is committed to developing innovative solutions to advance medical progress and make a positive contribution to human health. CSL is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CSL stock

Cash Conversion Rate (OCF/Net Income) of CSL is -136.18 % in 2026.

Cash Conversion Rate (OCF/Net Income) of CSL changed from 118.62 % to -136.18 %, representing a -214.80% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Rate (OCF/Net Income) CSL since 2006 – with annual values, charts, and detailed analysis.

Cash conversion measures how effectively net income converts to operating cash flow. Ratios above 100% indicate high-quality, cash-backed earnings.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Rate (OCF/Net Income)'s CSL with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Rate (OCF/Net Income)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Rate (OCF/Net Income).

Access this data via the Eulerpool API

Cash Flow — CSL

All Key Metrics — CSL